20Jan 2017

BONE CANCER- CURRENT PHARMACOTHERAPEUTIC APPROACH.

  • Deccan School of Pharmacy, Department of Pharmacy Practice, Darussalam, Aghapura, Nampally, Hyderabad Telangana, India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Bone cancer is a malignant (cancerous) tumor of the bone that destroys normal bone tissue. Malignant tumors that begin in bone tissue are called primary bone cancer. Primary bone cancer is far less common than cancer that spreads to the bones. Types of Primary bone cancer are Osteosarcoma, Chondrosarcoma. Diagnostic tests may include the following:-X-rays, Bone scan, Computed tomography (CT or CAT) scan, Magnetic resonance imaging (MRI), Angiogram. Treatment options depend on the type, size, location, and stage of the cancer, as well as the person’s age and general health. Treatment for bone cancer includes Surgery, Chemotherapy, Radiation therapy, and Cryosurgery. Surgery is one of the main treatments for primary bone cancers and is very specialized treatment. Chemotherapy works very well for some types of bone cancer, particularly Ewing\\\'s sarcoma. Radiotherapy called Intensity modulated radiotherapy (IMRT) to treat bone cancer. Cryosurgery is used to treat some types of low-grade cancerous and noncancerous tumors of the bone & is sometimes used instead of conventional surgery to destroy the tumor. Regular follow-up care ensures that changes in health are discussed and that problems are treated as soon as possible. Participation in clinical trials is an important treatment option for many people with bone cancer. NCI, a part of the National Institutes of Health, is sponsoring clinical trials in many hospitals and cancer centers around the country. Several cases of long bone giant cell tumor have been reported in the literature. We report the case of a patient with a giant cell tumor in the distal ulna. This is very unusual, with a reported incidence of 0.45 to 6%. A 17-year male presented with a painful swelling of the left wrist. After performing an instrumental examination, a diagnosis of distal ulna giant cell tumor was made. The tumor was treated with an intralesional curettage, phenol application and bone grafting. This tumor may have a good prognosis if it is diagnosed early and radically treated. It is important to be aware of atypical cancer localizations in order to perform a proper diagnosis.


  1. Bone cancer detailed guide American Cancer Society. Cancer Facts and Figures, 2016. Atlanta, Ga: American Cancer Society; 2016.
  2. Bjornsson J, McLeod RA, Unni KK, et al. Primary chondrosarcoma of long bones and limb girdles. Cancer. Vol:2008; Pgno:83-84
  3. Bovee JV, Cleton-Jansen A, Taminiau AH, Hogendoom PCW. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncology. Vol:2005; Pg no:599-607.
  4. Casali PG, Stacchiotti S, Grosso F, et al. Adding cisplatin (CDDP) to imatinib (IM) reestablishes tumor response following secondary resistance to IM in advanced chordoma. Vol:7 Pg no:282-284.
  5. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. Vol:2004; Pg no:101-110
  6. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an openlabel, parallel-group, phase 2 study,Vol:2013 Pg no:901-908.
  7. Epub 2013 Jul 16. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. Vol-2007; Pg no:40-47.
  8. Engels EA, Fraumeni Jr JF. New Malignancies Following Cancer of the Bone and Soft Tissue, and Kaposi Sarcoma. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, Vol:1973-2000.
  9. National Cancer Institute. NIH Publ. No. 05- 5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf.
  10. Gebhardt MC, Springfield D, Neff JR. Sarcomas of bone. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa.: Elsevier; Vol:2008: Pg no:2471-2572.
  11. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. Vol:2008; Pg no:320-329.
  12. Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. Vol:2009; Pgno:1063-1072.
  13. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget’s disease of bone. J Bone Miner Res. Vol:2006; Pg no:P58-63.
  14. Lewis DR, Ries LAG. Cancers of the bone and joint. In, Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07; Pg no:6215-6216.
  15. Bethesda, MD, 2007. Malawer MM, Helman LJ, O’Sullivan B. Sarcomas of bone. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; Vol:2011; Pg no: 1578-1609.
  16. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Bone Cancer. Version 1.2014.
  17. Accessed at www.nccn.org on January 6, 2014. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD).
  18. Accessed at http://omim.org/ on October 11, 2012. Springfield D, Rosen G. Bone tumors.
  19. DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine, 7th ed. Hamilton, Ontario: BC Decker;Vol: 2006;Pg no:1675-1693.
  20. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20(11): Pg no:1886-1894.
  21. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol.Vol: 2012;30(9):Pg no:914-920.
  22. Epub 2012 Feb 13. Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFRpositive chordoma. Ann Oncol. 2013;24(7): Pg no:1931-1936.
  23. Epub 2013 Apr 4. Tarpey PS, Behjati S, Cooke SL, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet. 2013;45(8): Pg no:923-926.
  24. Epub 2013 Jun 16. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009;21(4): Pg no:338- 344.
  25. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3): Pg no:275-280.
  26. Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2): Pg no:69-76.
  27. American Joint Committee on Cancer. Bone. AJCC Cancer Staging Manual. 7th ed. New York:.Springer-Verlag; Vol:2010 Pg no:281-287.
  28. Malawer MM, Helman LJ, O\'Sullivan B. Sarcomas of bone. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer:Principles and Practice of Oncology.  2. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2004.
  29. Pizzo P, Poplack DG, editors.Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2002.
  30. Ries LAG, Smith MA, Gur0650.ney JG, et al., editors.Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1999. Bethesda, MD: National Cancer Institute, 1999.
  31. Miller RW, Boice JD, Curtis RE. Bone cancer. In: Schottenfeld D, Fraumeni JF, editors.Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press, 1996.
  32. American Cancer Society (2008).Cancer Facts and Figures 2008Exit Disclaimer. Atlanta, GA: American Cancer Society. Retrieved March 13, 2008.
  33. Fischbach FT, Dunning MB.A Manual of Laboratory and Diagnostic Tests. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2004.
  34. Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K: The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004). Rare Tumors. 2009, 1: e52-PubMedPubMed CentralGoogle Scholar
  35. Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 1987, 69: 106-114.PubMedGoogle Scholar
  36. Goldenberg RR, Campbell CJ, Bonfiglio M: Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am. 1970, 52: 619-664.PubMedGoogle Scholar
  37. Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM: Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982, 64: 755-761.PubMedGoogle Scholar
  38. Masui F, Ushigome S, Fujii K: Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int. 1998, 48: 723-729. 10.1111/j.1440-1827.1998.tb03973.x.View ArticlePubMedGoogle Scholar
  39. Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y: Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res. 1999, 359: 176-188.View ArticlePubMedGoogle Scholar
  40. Malawer MM, Marks MR, McChesney D, Piasio M, Gunther SF, Schmookler BM: The effect of cryosurgery and polymethyl methacrylate in dogs with experimental bone defects comparable to tumor defects. Clin Orthop Relat Res. 1988, 226: 299-310.PubMedGoogle Scholar
  41. Marcove RC, Weis LD, Vaghaiwalla MR, Pearson R, Huvos AG: Cryosurgery in the treatment of giant cell tumors of bone. A report of 52 consecutive cases. Cancer. 1978, 41: 957-969. 10.1002/1097-0142(197803)41:3<957::AID-CNCR2820410325>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
  42. Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM, Canadian Sarcoma Group: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002, 397: 248-258.View ArticlePubMedGoogle Scholar
  43. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ: Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res. 2005, 435: 211-218.View ArticlePubMedGoogle Scholar
  44. Schajowicz F: Tumors and Tumor-like Lesions of Bone: Pathology, Radiology and Treatment. 1994, Springer-Verlag, ?View ArticleGoogle Scholar
  45. Gracia I, Proubasta IR, Trullols L, Peiró A, Moya E, Cortés S, Buezo O, Majó J: Distal radioulnar joint prosthesis for the treatment of giant cell tumor of the distal ulna: a case report and literature review. Strategies Trauma Limb Reconstr. 2011, 6: 103-106. 10.1007/s11751-011-0113-4.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Singh M, Sharma S, Peshin C, Wani IH, Tikoo A, Gupta SK, Singh D: Wide resection and stabilization of ulnar stump by extensor carpi ulnaris for giant cell tumor of distal ulna: two case reports. Cases J. 2009, 2: 8617-10.4076/1757-1626-2-8617.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Burke CS, Gupta A, Buecker P: Distal ulna giant cell tumor resection with reconstruction using distal ulna prosthesis and brachioradialis wrap soft tissue stabilization. Hand (N Y). 2009, 4: 410-414.View ArticleGoogle Scholar
  48. Ward WG, Li G: Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res. 2002, 397: 259-270.

[Ayesha Habeeb, Hafsah, Hafsa Sania ,Maryam Shaik, Misba Ali Baig, Syed Aamir Ali and Syed Amer.. (2017); BONE CANCER- CURRENT PHARMACOTHERAPEUTIC APPROACH. Int. J. of Adv. Res. 5 (1). 378-391] (ISSN 2320-5407). www.journalijar.com


AYESHA HABEEB
Pharma D, Deccan School of Pharmacy, Dar Us Salam, Nampally, Hyderabad.

DOI:


Article DOI: 10.21474/IJAR01/2757       DOI URL: http://dx.doi.org/10.21474/IJAR01/2757


Share this article